FindTrial
Sign In

PF-07321332

DRUG5 trials

Sponsors

Pfizer

Conditions

BioavailabilityCOVID-19Hepatic Impairment

Phase 1

Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
CompletedNCT05005312
PfizerHepatic Impairment
Start: 2021-08-31End: 2021-12-07Updated: 2023-09-06
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
CompletedNCT05263895
PfizerBioavailability
Start: 2022-03-03End: 2022-05-16Updated: 2025-06-11

Phase 2

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
CompletedNCT04960202
PfizerCOVID-19
Start: 2021-07-16End: 2022-04-25Updated: 2025-07-10
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
TerminatedNCT05011513
PfizerCOVID-19
Start: 2021-08-25End: 2022-07-25Updated: 2023-08-14
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
CompletedNCT05047601
PfizerCOVID-19
Start: 2021-09-09End: 2022-04-12Updated: 2023-05-06

Related Papers

Assessing participants' experiences with the COVID-19 symptom diary in a clinical trial.
2025-08-11
Patient-Reported Outcomes of Nirmatrelvir Treatment for High-Risk, Nonhospitalized Adults With Symptomatic COVID-19
Open Forum Infectious Diseases2025-07-302 citations
Integrated virologic analysis of resistance to nirmatrelvir/ritonavir in individuals across four phase 2/3 clinical studies for the treatment of COVID-19.
2025-06-30
Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial
Clinical Infectious Diseases2024-11-119 citations
Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19
New England Journal of Medicine2024-07-1723 citations
Clinical Trials of Respiratory Virus Infections: How to Address Challenges and Prepare for the Future
Infectious Diseases & Immunity2024-06-12
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
New England Journal of Medicine2024-04-03117 citations
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19
JAMA Network Open2024-02-0995 citations
Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID‐19
The Journal of Clinical Pharmacology2023-09-264 citations
Physiologically-Based Pharmacokinetic Modeling of PAXLOVID™ with First-Order Absorption Kinetics.
2023-05-2511 citations
1156. Sustained Alleviation and Resolution of Targeted COVID-19 Symptoms with Nirmatrelvir/Ritonavir versus Placebo
Open Forum Infectious Diseases2022-12-018 citations
786. Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations and Other Medical Visits
Open Forum Infectious Diseases2022-12-017 citations
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of <scp>COVID</scp>‐19, in Subjects With Renal Impairment
Clinical Pharmacology & Therapeutics2022-06-1763 citations
Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware
The Journal of Clinical Pharmacology2022-04-129 citations
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
New England Journal of Medicine2022-02-162087 citations
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology.
2022-01-1037 citations
12 Lektionen aus dem zweiten Corona-Jahr – und wer braucht Paxlovid?
EvidenzUpdate2021-12-30